EMJ Oncology 8 [Supplement 2] . 2020

In this issue

Cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with endocrine therapy (ET) are considered the standard-of-care treatment for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative (-) advanced breast cancer (ABC). The latest developments in the treatment of this cancer were covered during the European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, from 28th–29th September 2019.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?